SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

PluriCell wants to positively impact the lives of millions of patients suffering from chronic heart failure condition by injecting healthy bona fide lab-made human heart cells in their failing heart, improve its function and, ultimately, the clinical outcome of the patients. Our tech enables us not only tackle heart diseases, but potentially, many chronic disorders currenly untractable.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

CRIAM stands for Chemical Reaction and Image Analysis for Mobility. We are a Medtech startup born in January 2016 focused in the Point-of-Care diagnostic segment. Our mission is to provide fast, affordable and in-situ blood test analysis to empower people with instant information about their well-being and health conditions. With our device as a platform approach we will be able to monitor, control and contain diseases worldwide.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

CRIAM stands for Chemical Reaction and Image Analysis for Mobility. We are a Medtech startup born in January 2016 focused in the Point-of-Care diagnostic segment. Our mission is to provide fast, affordable and in-situ blood test analysis to empower people with instant information about their well-being and health conditions. With our device as a platform approach we will be able to monitor, control and contain diseases worldwide.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

Rize is a virtual marketplace for clinical trials. It is a patient management platform used to reinvent how patients and researchers interact. The company's patient-centric platform matches people with the appropriate clinical trial and offers the ability to participate digitally. Rize Health was founded in 2019 and is headquartered in London, Ontario.

Beeline is an early-stage preclinical cell therapy company developing the next generation of immune cell therapies for immune-mediated human disease, particularly diseases which result from the patient's own immune cells attacking healthy tissue. We are genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo and induce tolerance. In particular, we are re-engineering Regulatory T cells (Tregs) to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins, and combining enhanced Treg function with antigen specificity via targeting receptors for improved localization.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

TestSharing is a food tech platform that provides consumers with accessible and affordable professional lab testing for food safety. By utilizing a mobile application, users can scan the barcode of food items to receive detailed reports on the presence of pesticides and heavy metals. This innovative approach enables individuals to conduct a safety check on their food before consumption, enhancing informed decision-making about their dietary choices. The platform aims to empower consumers with critical information about the quality of the food they consume.

We are made up of a diverse range of cell types that can mutate or go awry, testing these cells to develop new therapies, to understand diseases or for biopsies is incredibly time-consuming. Cellari enables doctors and non-specialists to take full advantage of recent developments in artificial intelligence. Cellari are providing the most precise “active learning model” for bioimage segmentation combined with an intuitive and easy-to-use user interface for carrying out complex bioimaging tasks. An automated statistical testing service ensures statistical validity of clinical and research related results along with unparalleled review and methodology transparency functionalities.

CRIAM stands for Chemical Reaction and Image Analysis for Mobility. We are a Medtech startup born in January 2016 focused in the Point-of-Care diagnostic segment. Our mission is to provide fast, affordable and in-situ blood test analysis to empower people with instant information about their well-being and health conditions. With our device as a platform approach we will be able to monitor, control and contain diseases worldwide.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

PSG Therapeutics

CRIAM stands for Chemical Reaction and Image Analysis for Mobility. We are a Medtech startup born in January 2016 focused in the Point-of-Care diagnostic segment. Our mission is to provide fast, affordable and in-situ blood test analysis to empower people with instant information about their well-being and health conditions. With our device as a platform approach we will be able to monitor, control and contain diseases worldwide.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

CRIAM stands for Chemical Reaction and Image Analysis for Mobility. We are a Medtech startup born in January 2016 focused in the Point-of-Care diagnostic segment. Our mission is to provide fast, affordable and in-situ blood test analysis to empower people with instant information about their well-being and health conditions. With our device as a platform approach we will be able to monitor, control and contain diseases worldwide.

SocialSci operates an online platform that allows to conduct scientific process surveys and in lab studies by academic researchers. Its platform allows users to find studies in their local area that are looking for live participants, as well as to port their scientific research onto the online space. The company’s platform is used by colleges and universities in the United States. SocialSci was founded in 2009 and is based in Cambridge, Massachusetts.